HomeFileCoronary disease

Coronary disease

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been...

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention...

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed...

CALIPSO: Calcified Lesions and Use of OCT

Percutaneous coronary intervention (PCI) in calcified lesions remains one of the most challenging scenarios in daily practice,...

Retrospective Analysis of DCB vs DES in Side-Branch Treatment

Coronary bifurcations are one of the most challenging scenarios in percutaneous coronary intervention (PCI) due to their...

TCT 2025 | TUXEDO-2: Ultra-Thin Struts Versus Xience in Diabetic Patients with Multivessel Disease

It is well known that diabetic patients undergoing PCI often present with more extensive coronary artery disease,...

TCT 2025 | INVEST-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI

The success rate of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains lower than for...

TCT 2025 | INFINITY–SWEDEHEART: Long-Term Outcomes of the Bioadaptive Coronary Implant Versus Drug-Eluting Stent

The bioadaptive coronary implant DynamX (Elixir Medical, California) was developed to restore normal vascular function after angioplasty,...